00:49 , Aug 17, 2019 |  BioCentury  |  Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
21:32 , Aug 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocytosis protein decoy for reducing TRPV1-associated pain

DISEASE CATEGORY: Neurology INDICATION: Pain Blocking phosphorylation of endocytosis protein AP2M2 to induce internalization of TRPV1, a membrane channel associated with analgesia and hyperalgesia, could treat spontaneous pain and inflammatory thermal hyperalgesia. In an in...
19:29 , Aug 8, 2019 |  BC Innovations  |  Distillery Therapeutics

CDK7 inhibition for drug-resistant cancers

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma; solid tumors Inhibiting CDK7 could treat hedgehog signaling-driven cancers resistant to SMO inhibitors. A CDK7 inhibitor tool compound decreased viability of cells resistant to SMO inhibitors and driven...
21:47 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Dual stem cell therapy to enhance cardiac repair following MI

DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Epicardial implantation with a human mesenchymal stem cell (MSC)-loaded patch could enhance the efficacy of human iPS cell-derived cardiomyocytes for cardiac repair following MI. Administration of conditioned media...
04:39 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Stabilizing the closed form of RyR2 for nephrotic syndrome

DISEASE CATEGORY: Renal INDICATION: Renal damage Preventing podocyte injury by stabilizing the closed form of the calcium channel RyR2 could treat nephrotic syndrome. Phosporylation of RyR2's serine at position 2808 (S2808) causes calcium leakage through...
21:55 , Jul 24, 2019 |  BC Innovations  |  Distillery Therapeutics

Simultaneous CLEC5A and TLR2 inhibition for dengue

DISEASE CATEGORY: Infectious disease INDICATION: Dengue fever; viral hemorrhagic fever Simultaneously blocking CLEC5A and TLR2, both pattern recognition receptors linked to microbial infections, could improve survival following dengue virus infection. The inflammatory response to dengue...
18:51 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting EZH2 for colitis and colitis-associated colorectal cancer

DISEASE CATEGORY: Gastrointestinal; cancer INDICATION: Colitis; colorectal cancer Inhibiting EZH2 could help treat colitis and colitis-associated colorectal cancer. The EZH2 inhibitor GSK2816126 or a tool compound EZH2 inhibitor increased survival and colon length, which is...
18:47 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

Chemically induced knockdown of SMARCA2/4 to treat AML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Boehringer Ingelheim GmbH and University of Dundee showed that proteolysis-targeting chimeric molecules (PROTAC) targeting SMARCA2 and SMARCA4 could help treat AML. Chemical optimization guided by crystal structures...
23:34 , Jun 26, 2019 |  BC Innovations  |  Distillery Therapeutics

miR-17-92 gene therapy for ALS associated with SOD1 mutations

DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) A study from Taiwan's Academia Sinica suggests gene therapies encoding the miR-17-92 cluster could help treat SOD1-associated ALS. The cluster was previously reported to promote survival of...
20:06 , Jun 19, 2019 |  BC Innovations  |  Distillery Therapeutics

HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH

DISEASE CATEGORY: Hepatic INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH) Blocking hyaluronan synthesis, including via inhibition of HAS2 or its downstream effector NOTCH1, could help treat liver fibrosis. In hepatitis B, hepatitis C and NASH patients,...